Related Experiment Video
Updated: May 9, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Hemolysis Analysis and Hemolysis-related MicroRNA Candidates for Serum/Plasma Samples
1College of Medicine, North China University of Science and Technology, Tangshan (063000), Hebei, China.
Abstract:
Hemolysis is a major challenge in the screening and validation of serum or plasma miRNA biomarkers for human diseases. Over the past decade, numerous studies have focused on hemolysis detection at both the pre-analytical and postanalytical stages to minimize bias in miRNA quantification. Both conventional and advanced hemolysis determination methods have played important roles in quality control in hemolysis assessment and risk prediction during the plasma or serum miRNA quantification process. This review discusses the advantages of these methods and provides an interactive summary of prior knowledge on hemolysissensitive miRNAs and their potential applications in disease diagnosis. Furthermore, the review highlights the advancements in machine learning technologies that enhance classifier predictions and hemolysis risk model evaluations, particularly during the post-analytical stage. Finally, it discusses the ongoing development, standardization, and potential applications of these approaches, which will contribute to a more comprehensive and interpretable framework for the discovery and validation of plasma or serum miRNA biomarkers.

